Dynamic Technology Lab Private Ltd Makes New $1.05 Million Investment in Enovis Co. (NYSE:ENOV)

Dynamic Technology Lab Private Ltd acquired a new stake in Enovis Co. (NYSE:ENOV - Free Report) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 24,374 shares of the company's stock, valued at approximately $1,050,000.

Other large investors have also modified their holdings of the company. Ridgewood Investments LLC acquired a new position in shares of Enovis during the 2nd quarter worth about $44,000. DekaBank Deutsche Girozentrale acquired a new stake in Enovis in the 3rd quarter valued at about $55,000. Innealta Capital LLC purchased a new position in Enovis in the 2nd quarter worth approximately $65,000. Benjamin F. Edwards & Company Inc. boosted its holdings in shares of Enovis by 28.1% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 1,691 shares of the company's stock worth $76,000 after purchasing an additional 371 shares during the last quarter. Finally, Heritage Family Offices LLP acquired a new stake in shares of Enovis in the third quarter valued at approximately $206,000. Institutional investors and hedge funds own 98.45% of the company's stock.

Analysts Set New Price Targets

A number of analysts have issued reports on ENOV shares. JPMorgan Chase & Co. cut their target price on Enovis from $53.00 to $50.00 and set a "neutral" rating for the company in a research note on Thursday, August 8th. Needham & Company LLC reissued a "buy" rating and issued a $65.00 price objective on shares of Enovis in a report on Thursday, November 7th. Evercore ISI reduced their target price on shares of Enovis from $62.00 to $58.00 and set an "outperform" rating on the stock in a research note on Tuesday, October 1st. Finally, JMP Securities started coverage on shares of Enovis in a research note on Thursday, October 3rd. They issued an "outperform" rating and a $62.00 price target for the company. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $67.00.

Enovis Stock Up 1.5 %

Shares of NYSE:ENOV traded up $0.71 during trading on Wednesday, hitting $48.45. The company's stock had a trading volume of 475,747 shares, compared to its average volume of 582,486. The company has a market capitalization of $2.71 billion, a PE ratio of -21.80 and a beta of 1.91. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.12 and a current ratio of 2.27. Enovis Co. has a fifty-two week low of $38.27 and a fifty-two week high of $65.03. The business has a 50 day moving average price of $42.91 and a two-hundred day moving average price of $44.88.

Enovis (NYSE:ENOV - Get Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The company reported $0.73 EPS for the quarter, topping analysts' consensus estimates of $0.62 by $0.11. The business had revenue of $505.22 million during the quarter, compared to the consensus estimate of $504.44 million. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. The business's revenue for the quarter was up 21.0% on a year-over-year basis. During the same period in the previous year, the company posted $0.56 earnings per share. As a group, research analysts expect that Enovis Co. will post 2.79 EPS for the current fiscal year.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.